Mon, 01 Mar 2021

LONDON, UK / ACCESSWIRE / February 22, 2021 / Following the safety and tolerability data from the two Phase I trials in healthy volunteers, INM-755 is moving forward into a Phase II (755-201-EB) trial in up to 20 epidermolysis bullosa (EB) patients with an anticipated treatment duration of 28 days. Regulatory applications are expected to be filed in several countries in Q2 CY21 with enrolment to begin in the second half of the calendar year. Also, the formulation for INM-088 has been finalized with IND-enabling toxicology studies expected to begin in CY21 and filings for human clinical trials to begin in H1 CY22.

We have adjusted our valuation from US$233m or US$33.34 per basic share to US$236m or US$29.27 per basic share. The total valuation rose due to higher net cash following a financing, while the per-share value decreased due to a higher number of shares outstanding.

Click here to view the full report or here to sign up to receive research as it is published.

All reports published by Edison are available to download free of charge from its website www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutionffices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in ths, family oe darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Maxim Jacobs, +1 646 653 7027, healthcare@edisongroup.com

Nathaniel Calloway, +1 646 653 7036, healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv

SOURCE: Edison Investment Research Limited



View source version on accesswire.com:
https://www.accesswire.com/631081/InMed-Pharmaceuticals-INM-Phase-II-Enrolment-to-Begin-in-Second-Half

More Minneapolis News

Access More

Sign up for Minneapolis News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!